Lucid Diagnostics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Net Income	-47.03	-52.67	-56.17	-28.08	-8.28	-4.42
Depreciation & Amortization	2.39	2.5	1.94	0	0	0
Share-Based Compensation	4.55	6.82	14.99	9.6	0.07	0.17
Other Operating Activities	1.71	10.53	9.56	0.81	2.59	1.89
Operating Cash Flow	-38.38	-32.82	-29.69	-17.67	-5.63	-2.36
Capital Expenditures	-0.24	-0.22	-0.91	-0.86	0	0
Acquisitions	0	0	-3.2	0	0	0
Investing Cash Flow	-0.24	-0.22	-4.11	-0.86	0	0
Share Issuance / Repurchase	0.63	0.84	1.92	70	0	0
Debt Issued / Paid	0.08	10	0	7.74	5.58	2.5
Other Financing Activities	23.17	18.63	0.7	-5.66	0.01	-
Financing Cash Flow	23.87	29.46	2.61	72.08	5.58	2.5
Net Cash Flow	-14.75	-3.58	-31.18	53.55	-0.05	0.14
Free Cash Flow	-38.63	-33.04	-30.59	-18.53	-5.63	-2.36
Free Cash Flow Margin	-1294.84%	-1360.71%	-8114.85%	-3706.00%	-	-
Free Cash Flow Per Share	-0.86	-0.79	-0.85	-1.00	-0.40	-0.24

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).